



## Post Authorisation Assessments

### Hyogen Emulsion for Injection for Pigs

Vm 15052/3013

•	28 April 2024	<p>A new final product control test, testing the extractable volume of the finished product in addition to currently applied filling volume test performed during the filling process.</p> <p>To extend the shelf life of the vaccine from 15 months to 24 months.</p> <p>An additional new test measuring the paraffin oil content in the vaccine.</p> <p>A sandwich ELISA assay for antigen quantification using the same methodology, like the proposed in-vitro sandwich ELISA potency test. The proposed test is intended as in-process control test on the inactivated, concentrated antigen suspension.</p> <p>A new in-vitro method (sandwich ELISA assay) for control the potency of final product, replacing the current one, which is an in-vivo/iv-vitro test system measuring rabbit serology.</p> <p>Follow-up updates based on earlier variations.</p> <p>One-off alignment of the product information with version 9.0* of the QRD templates.</p>
•	16 November 2023	<p>Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).</p> <p>Introduction of a summary of the PSMF.</p>
•	27 January 2023	Increase in the batch size of the finished product.
•	13 October 2022	Change in the address of the MAH from Unit 3 Anglo Office Park, White Lion Road Amersham, Buckinghamshire HP7 9FB to Explorer House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, United Kingdom.
•	16 March 2022	Change in the SPC, labelling or package leaflet due to new data.
•	06 September 2021	Change in the fill volume of the finished product.
•	06 July 2021	Change in the manufacturer of a starting material used in the manufacturing process of the active substance.
•	23 June 2021	Replacement to a test procedure for the finished product.
•	10 June 2020	Replacement of a site where batch control/testing takes place.
•	27 March 2020	Renewal - UK as CMS.
•	21 November 2019	Changes in the SPC, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent

		authority under Articles 45 or 46 of Regulation 1901/2006.
•	21 November 2019	Increase in batch size of active substance or intermediate used in the manufacturing process of the active substance.
•	01 October 2019	Change to an approved stability protocol.
•	22 May 2019	Change in the fill volume of the finished product.
•	08 April 2019	Change in test procedure for an excipient.
•	31 January 2019	Change in the invented name of the veterinary medicinal product from Hyobloc (SE) and Mhyogen (DK) to Mhyogen vet in SE and DK.
•	19 September 2017	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS. Change of the back-up procedure of the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	08 August 2017	Replacement to a test procedure for the finished product.
•	06 October 2016	Change in the specification limits of the finished product. Change in the manufacturing process of the active substance.
•	20 September 2016	Addition of an alternative site for the animal testing phase of the potency test.
•	06 January 2016	Submission of an updated DDPS.